Fulltext

Soluble CD21 in sera and synovial fluid of arthritic patients

Grottenthaler, Thomas ; Kempis, Johannes ; Goldacker, Sigune ; Illges, Harald

In: Rheumatology International, 2006, vol. 26, no. 3, p. 240-243

Ajouter à la liste personnelle
    Titre
    • Soluble CD21 in sera and synovial fluid of arthritic patients
    Auteur
    • Grottenthaler, Thomas. Biotechnology Institute Thurgau, Konstanzerstr. 19, 8274, Tägerwilen, Switzerland
    • Kempis, Johannes. Division of Rheumatology and Clinical Immunology, Kantonsspital St.Gallen, 9007, St.Gallen, Switzerland
    • Goldacker, Sigune. Division of Rheumatology and Clinical Immunology, University of Freiburg Medical Center, Hugstetterstr. 55, 79106, Freiburg, Germany
    • Illges, Harald. Biotechnology Institute Thurgau, Konstanzerstr. 19, 8274, Tägerwilen, Switzerland
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • Rheumatology International, 2006, vol. 26, no. 3, p. 240-243. Springer-Verlag; http://www.springer.de
    Autre version électronique
    Identifiant OAI-PMH
    • oai:doc.rero.ch:316585
    Summary
    Soluble CD21 (sCD21) is the ectodomain of the CD21 glycoprotein released by shedding from the cellular membrane. The ectodomain of CD21 is capable of binding complement fragments, Epstein-Barr virus (EBV) and CD23. Functionally sCD21 can activate monocytes and abrogate B-cell/follicular dendritic cell interaction, thereby inhibiting antibody production by antigen primed B cells. Levels of sCD21 vary in several clinical conditions. Here we analyzed sCD21 in synovial fluids and sera in arthritic patients. sCD21 concentrations were consistently lower in synovial fluids compared to paired sera samples from the same patients. In contrast to healthy donors, sCD21 levels are significantly reduced in rheumatoid arthritis patient's sera. Potential causes and consequences of the data are discussed